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ABBREVIATIONS
AED Antiepileptic drugs
EAST Epilepsy, ataxia, sensorineural
deafness, and tubulopathy
GTCS Generalized tonic–clonic seizure
MAPER Multi-atlas propagation with
enhanced registration
TCS Tonic–clonic seizure
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AIM Recently, we reported a previously unrecognized symptom constellation comprising
epilepsy, ataxia, sensorineural deafness, and tubulopathy (EAST syndrome) associated with
recessive mutations in the KCNJ10 gene. Here, we provide a detailed characterization of the
clinical features of the syndrome to aid patient management with respect to diagnosis,
prognostic counselling, and identification of best treatment modalities.
METHOD We conducted a retrospective review of the detailed neurological and
neuroradiological features of nine children (four females, five males; age range at last
examination 6–20y) with genetically proven EAST syndrome.
RESULTS All children presented with tonic–clonic seizures in infancy. Later, non-progressive,
cerebellar ataxia and hearing loss were noted. Whilst seizures mostly responded well to
treatment, ataxia proved to be the most debilitating feature, with three patients non-
ambulant. All available magnetic resonance imaging (MRI) revealed subtle symmetrical
signal changes in the cerebellar dentate nuclei. Moreover, four patients had a small corpus
callosum and brainstem hypoplasia, and three had a small spinal cord. Regional quantitative
volumetric analysis of the images confirmed the corpus callosum and brainstem hypoplasia
and showed further patterns of variation from the norm.
INTERPRETATION The neurological features of EAST syndrome appear to be non-progressive,
which is important for prognostic counselling. The spectrum of EAST syndrome includes
consistent abnormalities on brain MRI, which may aid diagnosis. Further longitudinal
documentation is required to determine the true natural history of the disorder.
Mutations in genes coding for potassium channels have been
associated with a variety of hereditary diseases, including epi-
sodic ataxia, deafness, epilepsy, and cardiac arrhythmias.1–5
KCNJ10 (also called Kir4.1) encodes an inwardly rectifying
potassium channel that is expressed in renal epithelial cells,
inner ear cells, and glial cells in the central nervous system.6–8
Recessive mutations in this gene cause a newly recognized
syndrome characterized by epilepsy, ataxia, sensorineural
deafness, and tubulopathy (EAST syndrome).9,10 A similar
phenotype, but with neonatal lethality, is seen in KCNJ10
knockout mice.11–13 Few clinical reports characterizing the
phenotype currently exist in the literature; in particular, the
nature of the motor disorder and of the epilepsy have not
been demonstrated. Here we describe the neurological fea-
tures of nine children from six families with proven recessive
mutations in KCNJ10, in whom detailed neurological assess-
ment was performed, including imaging studies. Data were
collected under an NHS ethics approved protocol and parents
gave informed consent to publication of the report.
METHOD
Participants
The children were referred to Great Ormond Street
Hospital for clinical assessment at variable points in their
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natural history. All patients exhibited the four cardinal
symptoms of epilepsy, ataxia, sensorineural deafness, and
tubulopathy (Table I).
Magnetic resonance imaging (MRI) was performed using
a 1.5T Siemens Avanto or Symphony scanner (Siemens
Healthcare, Camberley, UK) and brain sequences obtained
included axial and coronal T2-weighted turbo spin echo
(TSE) images (retention time [TR] 4920ms, echo time
[TE] 101ms, slice thickness 4mm, matrix 3849245), volu-
metric three-dimensional (3D) T1-weighted magnetiza-
tion-prepared with rapid acquisition with gradient echo
(MP-RAGE) images acquired sagitally and reconstructed
in the orthogonal coronal and axial planes (TR/TE 11/4.9,
voxel size 1mm), and volumetric 3D fluid-attenuated inver-
sion recovery (FLAIR) images reconstructed in the axial
and coronal planes (TR/TE 6000/318, voxel size 1mm). In
the five patients who underwent targeted spine MRI, sagit-
tal T2-weighted TSE (TR/TE 3000/111, slice thickness
3mm) and T1-weighted TSE (TR/TE 465/11, slice thick-
ness 3mm) images were obtained. Further data were
obtained from medical records (including those of original
presentation); all available electroencephalograms and MRI
were reviewed. Mutation analysis and the electrophysiolog-
ical consequences of identified mutations in these patients
have been reported previously,8,9,14,15 as have the ophthal-
mological features.16
Volumetric analysis of MRI
T1-weighted magnetic resonance brain images were avail-
able for volumetric analysis for four patients and eight age-
and sex-matched comparison children imaged on the same
scanner. Volumetric brain image analysis on 83 regions
was carried out on the basis of anatomical segmentation
using multi-atlas propagation with enhanced registration
(MAPER; www.soundray.org/maper.)17 This automated
procedure consists of propagating a number of given atlas
label sets onto the target images using non-rigid image
registration, with subsequent consolidation of the resulting
segmentations into a single label set. The propagation
source comprised 30 atlases that had been generated
through manual delineation of 83 regions on T1-weighted
brain MRI acquired from young, healthy adults. Manual
segmentation protocols have been published previ-
ously.18,19 The accuracy and robustness of MAPER as well
as the validity of the resulting segmentations have been
shown extensively on a variety of normal and abnormal tar-
get images.17,20 An example of region identification by
automatic segmentation is given in supplemental figure 1.
Normative volumetric reference data were generated by
segmenting images from healthy individuals aged between
20 years and 30 years (n=83) from the IXI database (www.
brain-development.org). Labels of cortical regions contain-
ing grey matter or white matter portions (i.e. all regions
except ventricles, central structures, cerebellum, and brain-
stem) were multiplied with a binary grey-matter mask.
Regional volumes were normalized by intracranial volume.
Images of patients and age- and sex-matched comparison
children in this study were processed in an identical fash-
ion. Individual region sizes are expressed as score values
after z-transformation using the distribution of volumes in
the reference database.
RESULTS
Nine participants (five males, four females) were assessed at
ages 6 years 2 months to 20 years of age; five out of the nine
probands were offspring of consanguineous families of Paki-
stani origin. Of the remaining four, two were siblings of
Afro-Caribbean origin, one Iranian and one adopted (ethnic-
ity unknown). Detailed individual case histories are below. A
summary of the participants’ clinical features, as well as their
KCNJ10 mutation status is summarized in Table I. A video
demonstrating the movement disorder in one patient (5-2) is
provided in the online supplementary material.
Individual case histories
Patient 1-1
The family of patient 1-1 is of Pakistani heritage. This
female was born at term after an unremarkable pregnancy
by spontaneous vaginal delivery with a birthweight of
3.4kg. She fed and grew well for the first month of life,
but then developed irritability, poor feeding, constipation,
and failure to thrive, leading to elective admission at
4 months of age. Investigations at that time identified
hypokalaemic metabolic alkalosis. Potassium supplementa-
tion (8mmol/kg/d) accompanied by indometacin (2mg/kg/d)
administration, as well as nasogastric tube feeding, resulted
in good weight gain. Hypomagnesaemia with renal magne-
sium wasting was first noted at 3 years of age.
The first so-called short generalized tonic–clonic seizure
(GTCS) was noted at 4 months of age, during the child’s
first admission to hospital. She experienced multiple
GTCS (as recorded) during this hospital stay, which were
treated with diazepam, phenytoin, and eventually carba-
mazepine, which achieved good subsequent seizure control.
Surface electroencephalogram (EEG) at 5 months of age
was reported as showing spikes and sharp waves localizing
to the vertex. She was weaned from carbamazepine at
7 years of age with no seizure recurrence. However, noc-
turnal events subsequently occurred, and it remains unclear
whether these were epileptic in origin. Video-EEG teleme-
try at 16 years documented three stereotypical events with
no preceding EEG changes. The working diagnosis is
frontal lobe seizures.
Developmental delay was apparent from the end of her
first year: she sat unsupported at 1 year and walked
independently at 2 years of age. Moreover, ataxia became
apparent with a broad-based gait and intention tremor. At
What this paper adds
• Detailed delineation of the neurological features including response to AEDs
in a large patient cohort.
• Identification of subtle but characteristic MRI changes that may serve as
diagnostic criteria.
• Systematic differences in MRI between patients and comparison children
identified using a novel approach of volumetric analysis.
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9 years of age a trial of acetazolamide was given in an
attempt to improve the ataxia, but she developed severe
headaches and this medication was discontinued. She
attends a school for pupils with special needs.
At 5 years of age, she was noted to have hearing prob-
lems and was subsequently diagnosed with a sensorineural
hearing impairment for which she has been fitted with
hearing aids. To date, yearly audiograms show no definite
change in the hearing impairment.
At 16 years this patient reveals an ataxic wide-based gait
with no apparent truncal ataxia. There is evidence of past-
pointing, indicating cerebellar dysfunction. She has bilat-
eral brisk lower limb reflexes with extensor plantar
responses and mild facial dystonia, but normal tone else-
where.
Patient 1-2 (distant cousin of patient 1-1 and sibling of
patient 1-3 and patient 1-4)
Patient 1-2 was born at term after an uncomplicated preg-
nancy with a birthweight of 3.5kg. He first presented at
4 months with an apparent GTCS on awakening, lasting 3
to 4 minutes. Treatment with phenytoin was started at
4 months of age, but he continued to experience GTCS.
His antiepileptic medication was changed to valproate at
10 months of age, as he was believed to have developed
‘worsening tremors’ from phenytoin. However, his seizures
persisted, lasting 3 to 4 minutes and occurring, on average,
twice a month. He spontaneously became seizure free
between the ages of 4 years and 7 years 6 months. He was
weaned from valproate at 7 years 6 months of age and sei-
zures recurred, but were now of a focal nature, involving
staring episodes lasting up to 1.5 minutes, occurring two
or three times per day, with skin colour change. There
have been no GTCS since 4 years of age, but his focal
seizures persist. At his last examination, at 10 years of age,
he was being treated with lamotrigine and valproate, with
the frequency of his focal seizures being unchanged.
Mild hypomagnesaemia at 0.63mmol/L was noted at ini-
tial presentation, at which time he showed failure to thrive.
Hypokalaemia was first noted at 11 months of age, but
attributed to a concurrent gastrointestinal illness. At
3 years of age he presented again with an intercurrent
illness; hypokalaemia (2.2mmol/L) and hypomagnesaemia
(0.54mmol/L) led to suspicion of a tubulopathy and oral
electrolyte supplementation was instituted.
Neurodevelopment had been delayed from the outset:
he first sat unsupported at 2 years of age and walked
with support at 4 years of age. He has never gained full
independent walking. There has been no deterioration of
skills acquired, and there is a very slow but progressive
improvement in attempting to walk unaided. He was
noted to have a coarse tremor from an early age that
becomes more apparent when he performs any motor
task. He spoke his first meaningful words at 2 years of
age, making two-word sentences at 4 years of age. He
has slurring of speech with an explosive tone. He attends
a mainstream school with support but is currently not
achieving. He has moderate learning difficulties, with
evolving behavioural difficulties.
He was not recognized to have a hearing impairment. At
the age of 9 years, a formal audiological assessment was
attempted, but was unsuccessful owing to impacted ceru-
men and his motoric and behavioural difficulties.
At 9 years of age, this patient exhibits cerebellar signs,
with broad-based gait, intention tremor, titubation, dysdia-
dochokinesia, and dysmetria. He has no nystagmus. His
reflexes are normal, with normal tone and no ankle clonus,
and flexor plantar response. He has normal sensation, posi-
tion, and vibration sense, with no skeletal abnormalities.
Patient 1-3
This female was born at term after an uncomplicated preg-
nancy with a birthweight of 3.1kg. She first presented at
4 months of age with GTCS occurring in the early hours
of the morning. Biochemical testing at that time revealed
mild hypomagnesaemia (0.62mmol/L), but other para-
meters were normal. Treatment with valproate was com-
menced immediately because of previous experience with
the older sibling (patient 1-2), with good seizure control.
She has been seizure free from 4 months of age and she
continues to be treated with valproate. The parents noted
a coarse tremor from an early age with unsteadiness while
attempting any activity. She started walking with hands
held at 4 years and has recently started taking a few steps
unaided. She has difficulties with fine motor control as a
result of tremor, and often uses one hand to support the
other while eating or drawing. She spoke her first mean-
ingful words at 1 year 6 months of age and has been mak-
ing full sentences since 6 years of age. Her speech is
slurred with some scanning dysarthria. She attends a main-
stream school, where she has demonstrated mild learning
difficulties but no behavioural problems.
She was not recognized to have a hearing problem, but
audiological testing at the age of 6 years revealed high-
frequency hearing loss with absent otoacoustic emissions.
At 6 years of age, she has cerebellar signs, which include
gait ataxia, peripheral ataxia with dysdiadochokinesia, dysme-
tria, and titubation. Her reflexes are exaggerated with ankle
clonus but flexor plantar response. She has everted and plan-
tar-flexed feet, but no pes cavus or scoliosis. There is no nys-
tagmus with normal vision and extraocular movements.
Patient 1-4
This female is the youngest of three siblings (patients 1-2,
1-3). She first presented at 4 months of age with apparent
GTCS occurring during sleep. Since then, she has received
valproate, as did her sister, with complete seizure control.
Electrolytes at presentation were normal, with borderline
low potassium (3.8mmol/L) and magnesium (0.73mmol/L)
levels. Hypomagnesaemia has been noted intermittently
since 10 months of age.
An intention tremor was noted from a very early age.
She has truncal ataxia but she seems to be less affected
than her other two siblings. She has been walking indepen-
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dently since 3 years 6 months of age. Her gait is broad
based, but she is the most confident of her siblings, and
has shown gradual developmental progress. Her first mean-
ingful words were at 1 year of age. She is speaking full
sentences at present but with slurring of speech and an
explosive tone. She attends a mainstream school.
Like her siblings, a hearing problem was not recognized,
but audiological testing at the age 4 years revealed high-
frequency hearing loss with absent otoacoustic emissions.
On examination at 4 years of age, she has a broad-based
gait with tremors, head titubation, dysmetria, and dysdia-
dochokinesia. Her reflexes are normal, she has no ankle
clonus, and she has a flexor plantar response. She has no
nystagmus. Audiological testing revealed mild sensorineural
impairment.
Patient 2
This male of Pakistani heritage, reviewed at 16 years, is the
youngest of three siblings, the older two being fit and well.
The family migrated to the UK when he was 9 years old and
there are very limited medical records available from before
this time. He was born in Pakistan at term after an unre-
markable pregnancy with a birthweight of 3.1kg.
The family first lived in the United Arab Emirates, where
he presented at 5 months of age with a seizure that occurred
from sleep, involving stiffening of arms with facial twitching,
and loss of consciousness lasting 5 minutes. Phenobarbital
treatment was commenced for seizure control, and was
replaced with valproate at 6 months. Subsequently, he devel-
oped further apparent GTCS at 9 months of age, lasting
20 minutes. However, he remained seizure free from
9 months to 12 years of age and was weaned from valproate
at 4 years. At 12 years of age, he developed a tonic–clonic
seizure (TCS) from sleep with left-sided predominance
including left-sided facial twitching, lasting 20 minutes.
Valproate was recommenced. He currently experiences two
types of seizures; first, two or three daily episodes of behavio-
ural arrest associated with lip smacking and loss of awareness,
lasting up to 2 minutes and suggestive of focal seizures; sec-
ond, TCS which occur once every 6 months with a tendency
to be prolonged, and on two occasions resulted in intensive
care admissions for status epilepticus. Both seizure types have
continued despite treatment with phenytoin and valproate.
He was hospitalized at 2 years of age with a 4-day his-
tory of fever and vomiting. On admission, serum sodium
and potassium levels were 121mmol/L and 1.1mmol/L
respectively, leading to a diagnosis of a tubulopathy. He
was prescribed potassium supplements, indometacin, and
spironolactone.
Over time, an unstable broad-based gait with frequent
falls has manifested. On examination he has an intention
tremor, dysdiadochokinesia, and dysmetria. He has exag-
gerated lower limb reflexes, with an ankle clonus of 8 to
10 beats and extensor plantars. There is dystonic posturing
of the upper limbs on walking.
His development has been delayed: he crawled at 1 year
of age, walked independently at 2 years 6 months of age,
and currently falls frequently while walking. He spoke his
first meaningful words at 2 years of age, with current slow
and slurred speech. He is in special education. EEG at
13 years while on valproate and phenytoin medication
showed waves of low amplitude and low frequency. No
epileptiform discharges were seen, but a mild excess of
slow-wave activity was observed, intermixed in the poster-
ior regions with 2 to 3Hz sharp-wave activity. Repeat
EEG at 16 years was normal.
He was suspected of having a hearing problem at the
age of 15 years. Subsequent audiological testing revealed
sensorineural hearing loss.
Patient 3
This male is of Iranian heritage and his first reported pos-
sible seizure occurred during the neonatal period, with
generalized stiffening for less than 20 seconds, with spon-
taneous resolution. At 2 months, further seizures were
reported but no further details are available. Treatment
with phenobarbital led to seizure control. Subsequently he
continued to have a TCS once every 6 to 12 months,
always during sleep, which responded to a weight-adjusted
dose of phenobarbital. Phenobarbital treatment was main-
tained until 7 years of age, when it was replaced with
lamotrigine with subsequent seizure control.
At 6 years of age, he presented with vomiting and leth-
argy associated with a viral illness and was noted to have a
potassium level of 2.2mmol/L. Subsequent measurements
and 24-hour urine sampling reportedly demonstrated renal
potassium loss and a tubulopathy was suspected. The par-
ents state that whenever he had a gastrointestinal illness
and low potassium values, he had difficulties in moving.
Magnesium losses were noted later.
He learned to walk by 7 years of age with a broad-based
gait and ataxia and has not deteriorated. He received regu-
lar physiotherapy from 3 until 14 years of age, requiring
splints, Pedro boots, insoles, and orthotics. A tremor was
first noticed at 3 years 6 months of age, this being worse
in the morning. He was noted to frequently spill from a
cup, and is not able to use a fork at present. He can use
zippers, but is unable to do up buttons. He uses a com-
puter to aid his writing skills.
Speech was slurred and slow from an early age and is, at
present, explosive. He spoke his first word at 3 years, and
at 16 years has a total of 30 spoken words. He has received
regular speech therapy throughout his school years.
His parents noted that he did not respond to noises
from as early as 1 to 2 years of age, and a formal hearing
test at 5 years revealed sensorineural deafness requiring
hearing aids. Examination showed ataxia with past-pointing
and dysdiadochokinesia; he has generalized increased tone
with brisk deep tendon jerks and extensor plantar response.
Patient 4
This male presented aged 2 months with generalized
stiffening of the whole body, occurring on awakening. He
was adopted as an infant and family history and ethnicity
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are unclear, as are further details of his early seizure
history. He was extensively investigated at 18 months of
age and was treated with carbamazepine, which was later
replaced with lamotrigine. He continues to have apparent
GTCS requiring occasional hospitalization. At 5 years,
biochemical investigations revealed a hypokalaemic, hypo-
chloraemic metabolic alkalosis. He was noted to have
developmental delay at 2 years 6 months of age, with evi-
dence of ataxia. He achieved walking with the aid of a
walking frame. Since the age of 11 years, he has had diffi-
culties supporting his weight and has been using a wheel-
chair. He had speech delay; sensorineural deafness was
detected at age 2 years 6 months necessitating a hearing
aid. He is currently able to speak in short simple sentences.
No formal speech assessments have been performed. He
has been in special education throughout his school years
and at 20 years of age lives in a residential college with the
aim of acquiring independence skills.
At 20 years of age, he exhibits past-pointing and dysdia-
dochokinesia with a scanning dysarthric speech. His deep
tendon reflexes are present, but not exaggerated. There is
a suggestion of dystonic posturing of the fingers when
stressed.
Patient 5-1
The older of two siblings of Afro-Caribbean origin, this
female presented at 3 months of age with a reported
GTCS. Treatment with valproate was initiated. Seizures
were not considered problematic, and she remained seizure
free from 4 to 8 years of age. On an attempted wean from
valproate, she was troubled by frequent TCS as well as
non-convulsive status epilepticus. Control was not regained
on reintroduction of valproate, but she became, and
remains, seizure free on lamotrigine.
She was not suspected of having a hearing problem, but
when screened at the age of 15 years, after her younger
brother (patient 5-2) was diagnosed with hearing loss, she
was also found to have high-frequency hearing loss.
Electrolytes were first measured at the age of 18 years
and revealed hypokalaemic alkalosis and hypomagnesaemia.
She was noted to have increased tone and unsteadiness
from infancy. She did attain independent walking at
17 months; however, with the deterioration in seizure con-
trol at 8 years she lost mobility and this has not been
regained. Her gait shows elements of ataxia; she has inten-
tion tremor, dysmetria, and dysdiadochokinesia. There is
also apparent dystonia with bradykinesia. There is increased
tone in the lower limbs, and no clear clonus, but there are
extensor plantar responses. She has a scoliosis. She also has
global cognitive difficulties, with the gap widening between
her and her peers over the years (18y of age at last review);
however, there has been no period of loss of cognitive skills.
Patient 5-2
This male is the younger brother of patient 5-1. He expe-
rienced onset of seizures at 6 months with a self-limiting
GTCS. He subsequently had three afebrile seizures at
9 months. He then had no further seizures until 4 years of
age, when he developed left focal seizures. These
responded to lamotrigine after failed trials of valproate and
levetiracetam.
Plasma electrolytes were first checked at initial presenta-
tion and included a normal plasma potassium value of
4.4mmol/L. At the age of 5 years, plasma potassium was
borderline low at 3.8mmol/L. Magnesium was not tested on
either occasion. At 10 years of age he has hypokalaemia
(3.3mmol/L), but normal plasma magnesium (0.74mmol/L).
His hearing was first tested at the age of 4 years and
revealed sensorineural deafness for which he was fitted
with hearing aids.
He began to walk late: at 2 years of age. At the age of
10 years he has an ataxic gait but is able to run. He has
intention tremor and dysmetria. His speech also has a cere-
bellar quality. Muscular tone is symmetrically increased
but there is no clonus and flexor plantar response. He is
cognitively behind his peers, but making progress.
Epilepsy
All children in the above cases presented with seizures
early in the first year of life. These were all described in
the records as GTCS, although it could not be determined
whether they were primarily or secondarily generalized. In
six of the patients, epilepsy was initially controlled with an-
tiepileptic drugs (AEDs) at presentation; the three others
were still experiencing seizures at admission but they later
achieved remission. In all but the youngest two patients
(6y 4.8mo and 4y) focal seizures later re-emerged (with or
without progression to bilaterally convulsive seizures), but
were readily controlled with AEDs in four of the patients.
One underwent video-EEG telemetry to document events
from sleep at 16 years; all events were stereotyped but
there was no consistent EEG change. Despite the unre-
markable EEG findings, the consistent stereotyped nature
led to a diagnosis of frontal lobe seizures, which did indeed
respond to a single AED. Lamotrigine has been the effec-
tive medication when trialled in three children, whereas
two others responded to valproate. Three children con-
tinue to have drug-resistant seizures of apparent focal
onset. There was no apparent relationship between drug
resistance and age.
Neurological development and motor disorder
All children had evidence of early motor delay in their his-
tory. Two children (patient 1-2 and patient 4) have never
achieved independent walking as a result of ataxia. Age at
walking in others ranged from 17 months to 7 years. All
have been unsteady to a variable degree with frequent falls
from the onset of walking, suggesting ataxia from the out-
set, with only two patients (patient 5-1 and patient 5-2)
reporting a history of steady deterioration. Patient 5-1
walked at 17 months, but this was lost after a prolonged
seizure at 8 years. All children were reviewed at a single
point in time rather than on serial examinations. However,
even within the same family, there is a degree of pheno-
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typic variability, with no obvious relationship between
severity of motor impairment and age. In family 1, the
three siblings (patient 1-2, patient 1-3, and patient 1-4)
were reviewed at 9 years, 6 years, and 4 years. The middle
child walked at 6 years and retained the skill, whereas the
oldest child has never walked and the youngest achieved
independent walking at 2 years.
All the patients who are ambulant walk with a broad-
based ataxic gait. All show evidence of dysmetria, dysdia-
dochokinesia, and intention tremor. One has scoliosis. All
have brisk deep tendon jerks, but all except two (patient 13
and patient 2) show no evidence of clonus. There is the
suggestion that tone increases with age, with dystonic
posturing more evident in the older children.
Detailed neuropsychological assessments have not been
carried out, but all children have shown a degree of cogni-
tive delay since the first year of life, with all demonstrating
mild to moderate learning difficulties at clinical review. All
have shown steady cognitive improvement, albeit slow
when compared with their peers. Five have a statement of
special educational needs.
Investigations
Neuroimaging
Neuroimaging was available for review in six of the nine
children; complete brain and spine MRI was conducted in
three and brain MRI alone or with additional limited spine
imaging was conducted in the other three. Two children
underwent repeat brain MRI (8y and 10y after the initial
scan), and these showed no evidence of progressive change.
Age at imaging was ranged from 9 to 19 years. MRI in all
six children showed symmetrical signal abnormality of
varying severity in the cerebellar dentate nuclei and dentate
hila (see Fig. 1). All six also showed evidence of cerebellar
hypoplasia, of varying severity. The cerebellar hypoplasia
was most severe in patient 5-1, affecting the cerebellar ver-
mis and both cerebellar hemispheres, with the pons
appearing normal. Four children had a thin corpus callo-
sum, reflecting the lack of white matter bulk. The same
four children had some degree of brainstem hypoplasia
(see Fig. 2). Three children had a thin spinal cord (see
Fig. 2). All three of the children with complete spinal
imaging also had a fatty filum terminale with normally
positioned conus medullaris (see Fig. 2).
Quantitative image analysis. Morphometric analysis of the
brain reveals a systematic influence that EAST pathology
appears to have on the entire brain’s anatomical configura-
tion (Fig. 3). Consistent with the radiological interpretation
of the MRI, region volumes in the brainstem and corpus
callosum were reduced. Variations in ventricular size were
evident, with large lateral ventricles and small temporal
horns. Reductions in thalamic volume were also substantial.
Audiology
A detailed hearing assessment was performed in eight chil-
dren, using tympanometry, pure-tone audiometry, and
otoacoustic emissions. In only six patients was hearing loss
clinically suspected before testing; audiometry revealed
high-frequency hearing loss in all eight patients assessed;
whereas tympanometry was normal in all. Otoacoustic
(a)
(d)(c)
(b)
(e) (f)
Figure 1: Patients with EAST syndrome show increased signal intensity of the cerebellar nuclei and cerebellar hypoplasia on brain magnetic resonance
imaging. Coronal T2 or fluid-attenuated inversion recovery images show varying degrees of signal hyperintensity in the cerebellar deep nuclei. These
ranged from subtle signal changes in comparison with the cerebellar cortex to more obvious changes within both the cerebellar deep nuclei and hilar
white matter. (a) patient 1-1, (b) patient 2, (c) patient 4, (d) patient 3, (e) patient 5-1, and (f) patient 5-2.
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emissions could be assessed in five children and were
absent in all.
Other investigations
These included EEG (n=5), nerve conduction studies (n=5),
and metabolic evaluation. EEG was abnormal on only one
occasion in one patient, showing spikes and sharp waves
with slow activity over one hemisphere; subsequent EEG
was normal. The remaining investigations performed
revealed no abnormality. Three children underwent muscle
biopsy and one a skin biopsy, all of which were also reported
histologically as normal. These studies were undertaken
before the diagnosis of EAST syndrome was made.
DISCUSSION
A clinical syndrome characterized by epilepsy, ataxia, senso-
rineural deafness, and tubulopathy, EAST syndrome, has
recently been linked to recessive mutations in the KCNJ10
gene.9 Here we further delineate the neurological findings in
nine children (including two sets of siblings). Key features
include early-onset epilepsy, unrelated to the electrolyte
imbalance, but readily controlled by antiepileptic medica-
tion. Although documented by description as generalized
seizures, it remains unclear whether these were indeed sec-
ondarily generalized seizures with focal onset as might be
expected in this age group.21 In many patients, the epilepsy
is later characterized by more apparent focal seizures. Motor
delay is apparent from the first year of life, with evident
ataxia at the time of independent walking, if achieved. In
most patients, the ataxia appears to be persistent and non-
progressive, although in one child definitive deterioration of
motor function was seen, possibly related to the occurrence
of a prolonged seizure. There is the impression of increasing
tone with age, with dystonic posturing seen in older chil-
dren. Thus, EAST syndrome appears to have both static and
progressive features, in contrast to the episodic or self-limit-
ing disease seen in other potassium channelopathies with
neurological features.22
Ion channel mutations are being increasingly associated
with specific epilepsy syndromes. These syndromes may
include single or multiple seizure types, and may have a
benign or a more complex course.23 Notably, mutations in
the potassium channel gene KCNQ2 have been linked to
benign familial neonatal convulsions, a syndrome in which
seizures are seen in the neonatal period only and are
self-limiting, with normal subsequent neurological develop-
(a) (b)
(c) (d)
Figure 2: Other abnormalities on brain magnetic resonance imaging. (a) Axial T2-weighted and coronal volumetric fluid-attenuated inversion recovery
images in patient 3 show bilateral symmetrical signal hyperintensity within the cerebellar deep nuclei and hilar white matter (arrow) and a retrocerebel-
lar arachnoid cyst. This child also has a fatty filum terminale but normal position of the conus medullaris and no other spinal dysraphic features (not
shown). (b) Coronal and axial T2-weighted images in patient 5-2 show prominence of the cerebellar hemisphere and vermian fissures. Note again the
subtle symmetrical dentate nucleus changes (arrow). (c) Sagittal T1-weighted image (patient 1-1) shows normal position of the conus medullaris, a fatty
filum terminale, and normal spinal cord volume. (d) Sagittal T1- and axial T2-weighted brain images (patient 2) show global lack of cerebral volume with
slightly thin corpus callosum and brainstem and spinal cord hypoplasia.
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ment.24 The patients described here, all with mutations in
the gene encoding the inwardly rectifying potassium
channel, KCNJ10, presented in the first year of life with
isolated apparent GTCS, although in this age group focali-
ty of onset may be difficult to determine.21,25 These initial
seizures, on the whole, responded well to treatment with
antiepileptic drugs; however, the possibility of a biphasic
presentation, initially self-limiting but with re-emergence
Figure 3: Comparative size of individual regions in patients (Pat) and matched comparison children (Ctl), represented as z-scores, using the IXI cohort
as a normative reference. Coloured discs, individual patients; black discs, patient median; rings, comparison median; black lines, interquartile range of
comparison group. Coloured rectangles indicate whether the patient median z-score is larger (red) or smaller (blue) than the comparison median
z-score. Regions where the difference is significant (as determined by a Wilcoxon unpaired ranked-sum test, alpha=0.05, no correction for multiple
comparisons) are marked with an asterisk (*). The colour intensity of the rectangles also represents significance. Regions are grouped anatomically,
with groups separated by dotted lines. From top to bottom: temporal lobe, frontal lobe, cerebellum and brainstem, insula and cingulate gyri, occipital
lobe, parietal lobe, central structures, ventricles. R, right; L, left; ant, anterior; temp, temporal; med, medial; lat, lateral; sup, superior; post, posterior;
frt, frontal; inf, inferior; ct, cortex; g, gyrus; gg, gyri; l, lobe; rem, remainder; G parahippocamp/amb, gyrus parahippocampalis et ambiens.
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of seizures at a later age, needs to be considered. Later
presentation appears to involve more definitive focal sei-
zures (of differing semiology between individuals) and,
again, is relatively easily controlled with antiepileptic medi-
cation in most patients.
Inwardly rectifying potassium channels such as KCNJ10
are thought to be involved in the spatial buffering of potas-
sium by mediating potassium movement from areas of high
extracellular concentration, thus lowering neuronal excit-
ability.26 Genetic variations in KCNJ10 have been previ-
ously implicated in seizure susceptibility in idiopathic
generalized epilepsy syndromes.27,28 Notably, lamotrigine,
which is known to suppress repetitive firing through inacti-
vation of voltage-gated sodium channels once cells are
depolarized,29 was effective in three individuals in whom it
was trialled, thereby linking the clinical effect to a possible
mode of action.
The motor disorder seen in our patients is difficult to
characterize. Ataxia was seen in all, manifesting from the
time of walking and appearing non-progressive in most.
Manifestations of poor pelvic control were demonstrated in
those who were non-ambulant, giving the impression of a
peripheral muscular disorder, but nerve conduction studies
as well as muscle biopsy were normal where they were per-
formed. Further, increasing tone was seen with age, as dys-
tonic posturing was seen in the older children. Cognitive
abilities appeared impaired in some, but did not deterio-
rate. Early and severe ataxia can affect verbal and written
communication, and therefore may have confounded the
assessment. Thus, the term intellectual disability* is not
appropriate for all patients with EAST syndrome.30
Visual MRI analysis, when available, showed consistent
abnormalities with respect to cerebellar volume (suggestive
of hypoplasia) and signal change in the dentate nuclei. Such
changes, therefore, could be put forward as part of the clini-
cal diagnostic criteria. Further, they provide a structural cor-
relate to the ataxia. In addition, brainstem hypoplasia and a
thin corpus callosum were seen in four of the six patients
and spinal cord abnormalities were seen in three. The iden-
tification of these abnormalities is in contrast to our initial
report, in which MRI in two patients was considered nor-
mal.9 This demonstrates the difficulties of assigning the
judgement of normal or abnormal to subtle changes. If seen
in an isolated patient, such changes may represent a variant
of normal; however, if the changes are present in several or
all patients with the same disorder, they are likely to repre-
sent a feature of the disease. Indeed, the unbiased and
detailed morphometric analysis confirmed several of these
changes: the brainstem and the corpus callosum are signifi-
cantly smaller in patients than in comparison children. In
addition, it revealed systematically smaller volumes in tem-
poral cortical regions, as well as larger volumes in the frontal
lobe. These findings have to be interpreted with care,
because of the small number of participants, and because we
did not correct for multiple comparisons after applying the
Wilcoxon ranked-sum test to each individual region.
Despite these caveats, the impression of systematic change
from the visualization in Figure 3 is distinct. It is not clear
how dysfunction of KCNJ10 causes these morphological
abnormalities, but the channel has been implicated in myeli-
nation in mice. KCNJ10 knockout mice present with pro-
found ataxia and late stimulus-sensitive seizures, with early
mortality.13,31
The volumetric analysis is complementary to visual analy-
sis and no replacement for expert neuroradiological assess-
ment: in the case of clear volumetric abnormalities, these
will be detected by both analyses (e.g. patient 3; Figs 1d and
3 [individual volumes for this child]). Pure FLAIR signal
changes without volumetric repercussion, or widened cere-
bellar sulci less than a voxel wide (e.g. patient 5-2; Fig. 1f)
will be easily detectable by visual analysis but invisible to
MAPER. Subtle changes in absolute volume, however, are
very hard to detect visually. The presence of such systematic
volumetric change in various brain areas is strongly
suggested from the visualization of the MAPER results in
Figure 3, demonstrating the power of this approach.
CONCLUSION
Our study raises several important points concerning the
clinical features of EAST syndrome. First, we found that
infantile onset of seizures was a consistent presentation in
all the patients studied. This was followed by the later re-
emergence of more definitive focal seizures. In general,
however, the prognosis for seizure control appears good.
Second, high-resolution MRI revealed consistent cerebellar
changes in all patients examined, providing a further diag-
nostic tool, as well as a likely morphological correlate to
the ataxia. Third, automatic brain image analysis also
revealed a characteristic pattern of morphological change.
Fourth, we identified no clear evidence for a progressive
course of the disease, an important point invariably raised
by affected families, who want to know what to expect for
the future. However, longitudinal studies of individual
EAST patients are required to clarify this point.
ACKNOWLEDGEMENTS
UCL Institute of Child Health received funding as a National
Institute for Health Research Specialist Biomedical Research Cen-
tre. DB is a Higher Education Funding Council for England
(HEFCE) Clinical Reader.
SUPPORTING INFORMATION
Additional supporting information may be found in the online
version of this article:
Video S1: Video of patient EAST 5-2 at age 10 years demon-
strating ataxic gait, dystonic posturing of the upper limbs on
stressed walking, and intention tremor.
Figure S1: Brain regions are correctly identified by automatic
segmentation. Axial, coronal, and sagittal sections of T1-weighted
image of patient 5-1 show examples of anatomical regions as
identified by the automatic segmentation algorithm, highlighted
by coloured contours.*North American usage for mental retardation
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